12:00 AM
Mar 13, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

VAS991: Began efficacy trial

Vasogen Inc. (TSE:VAS; MEW), Mississauga, Ontario
Product: VAS991
Business: Cardiovascular
Therapeutic category: Immune modulation...

Read the full 48 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >